Biogen has agreed to pay $900 million to resolve allegations stemming from a whistleblower lawsuit alleging the drugmaker paid kickbacks to physicians to induce them to prescribe the company's multiple sclerosis drugs.
Biogen has agreed to pay $900 million to resolve allegations stemming from a whistleblower lawsuit alleging the drugmaker paid kickbacks to physicians to induce them to prescribe the company's multiple sclerosis drugs.
